Short-term response to MET inhibitors observed in multiple clinical trials as well as dis-concordant efficacy of immunotherapy leads to the following hypothesis: there is an inter-patient/tumor heterogeneity with clinical and biological significance in patients with METex14 NSCLC21. This evidence concerns the gene MET and neoplasm.